Arena Pharmaceuticals (ARNA) Key Priorities Plan; Infinera (INFN) Surpasses Estimates


Shares of Arena Pharmaceuticals, Inc. (Nasdaq:ARNA) climbed more than 2% in after-hours trading Tuesday as the company said that it will implement a strategic plan that includes a 35% reduction of U.S. workforce, aiming for about $11.0 million in personnel-related annual cost savings, and another measures to boost efficiency.

ARNA stock finished the regular session at $2.20, down $0.01 (or -0.45%), and 1,334,770 of its shares exchanged hands during the day

Arena Pharmaceuticals, a biopharmaceutical company, has 242.24M Shares Outstanding, Market Capitalization (intraday) of $532.93M and ARNA stock 52-week range is between $1.73 and $6.28 per share.



Infinera Corporation (Nasdaq:INFN) shares closed at $10.42, down $0.15 (or -1.42%) on Tuesday’s trading session. After the closing bell, the company delivered stronger-than-expected quarterly profit and revenue in its financial results

For the third quarter 2015, Infinera posted revenues of $232.5 million and non-GAAP net income of $32.2 million, or $0.22 per diluted share, topping the Capital IQ Consensus Estimate of $0.17 earnings per share on revenues of $225.77 million for the period

INFN stock surged more than 8% in the extended session, following the release of the company’s earnings report

Infinera, which provides Intelligent Transport Networks, has 131.21M Shares Outstanding, Market Capitalization (intraday) of $2.40B and INFN stock one-year range is $13.00 – $25.24 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at